Adoption of HIV nucleic acid testing and automation to spur market growth

Over 32% of HIV+ people in Europe remain undiagnosed. This large untapped pool and the development of novel nucleic acid test (NAT) and non-NAT technology based platforms offers growth potential for HIV diagnostics manufacturers.

Photo: Adoption of HIV nucleic acid testing and automation to spur market growth

New analysis from Frost & Sullivan Analysis of European HIV Diagnostics Market, finds that the market is estimated to expand from $797.1 million in 2012 to approximately $1,164.4 million in 2019. The research covers HIV NAT diagnostics and immunodiagnostics.

“Rising public awareness about HIV is boosting test volumes,” notes Frost & Sullivan Senior Research Analyst K. Srinivas Sashidhar. “This has motivated the development of new products based on NAT and non-NAT technology platforms. The introduction of such innovative diagnostics products will be the key success factor in this market.”

Heightened interest in companion diagnostics and the adoption of automation in laboratories will reinforce market growth.

“There is a significant need for highly sensitive HIV/AIDS assays in the market, which can detect very low levels of viral RNA copies,” comments Sashidhar. “Companies are developing automated platforms to remain competitive.”

In addition, there is a greater need to recognise the correlation between virus mutations and the efficacy of various antiretroviral therapies (ARTs). Companion diagnostics are a key solution to understanding this correlation.

“Viral genotyping is a popular trend to determine mutations in the HIV genome as they mostly lead to drug resistance,” adds Sashidhar. “These demands will spur innovation, while driving market growth throughout the forecast period.”

For a variety of reasons, the level of undiagnosed population in Europe remains quite high. The biggest challenge for market participants is thus to identify and tap into this segment.

Proper education and awareness will help boost test volumes and demand for HIV diagnostic kits. Effective, low-cost offerings, together with a wide range of services including periodic kit demonstrations, can advance market prospects.
 

26.02.2013

Read all latest stories

Related articles

Photo

HIV

Researchers date 'hibernating' HIV strains

Researchers have developed a novel way for dating "hibernating" HIV strains, in an advancement for HIV cure research in the province. The HIV cure research confirms that dormant HIV strains…

Photo

Cautiously optimistic

Despite a slight drop in sales in 2013 compared to the previous year, for 2014 the German medical diagnostics manufacturers anticipate a positive business development, according to the trend…

Photo

Denmark’s top-class robot technology

Copenhagen’s Hilleroed Hospital now has the world’s most advanced medical laboratory system, providing full automation from the point of drawing a blood sample to results delivery.

Related products

Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
ASP Lab Automation – Bench-top Decapper DeCap Pro

Sample Processing

ASP Lab Automation – Bench-top Decapper DeCap Pro

ASP Lab Automation AG
Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Horiba Medical – HELO* Solution

Automation

Horiba Medical – HELO* Solution

HORIBA Medical